Home > Insider Trading > Filing (0001144204-15-066784)

Filing Details

Accession Number:: 0001144204-15-066784
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-18 17:33:51
Reporting Period:: 2015-11-16

Filing Date:: 2015-11-18
Accepted Time:: 2015-11-18 17:33:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293310	Kalobios Pharmaceuticals Inc	KBIO	Pharmaceutical Preparations (2834)	770557236

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1658549	Anthion Partners Ii Llc	379 West Broadway New York NY 10012		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-11-16	225,963	$1.26	293,900	No	4	P	Direct
Common Stock	Acquisiton	2015-11-16	225,963	$1.26	293,900	No	4	P	Indirect	Through Anthion Partners II LLC
Common Stock	Acquisiton	2015-11-16	17,100	$1.76	311,000	No	4	P	Direct
Common Stock	Acquisiton	2015-11-16	17,100	$1.76	311,000	No	4	P	Indirect	Through Anthion Partners II LLC
Common Stock	Acquisiton	2015-11-17	113,800	$1.69	424,800	No	4	P	Direct
Common Stock	Acquisiton	2015-11-17	113,800	$1.69	424,800	No	4	P	Indirect	Through Anthion Partners II LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	Through Anthion Partners II LLC
No	4	P	Direct
No	4	P	Indirect	Through Anthion Partners II LLC
No	4	P	Direct
No	4	P	Indirect	Through Anthion Partners II LLC

Footnotes

The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 225,963 shares in multiple transactions at prices ranging from $0.7 to $1.69, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
The securities reported herein are owned directly by Anthion Partners II LLC and indirectly by David Moradi, the Managing Member of Anthion Partners II LLC. Both Anthion Partners II LLC and David Moradi are members of a "group" (with other persons) for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, neither Anthion nor Mr. Moradi have a pecuniary interest in the shares owned by the other members of the group.
The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 17,100 shares in multiple transactions at prices ranging from $1.7 to $1.85, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
The prices reported in Column 4 are weighted average prices. Anthion Partners II LLC, on behalf of David Moradi, the Managing Member of Anthion Partners II LLC, purchased 113,800 shares in multiple transactions at prices ranging from $1.42 to $1.96, inclusive. The reporting persons undertake to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.